Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
| Tamaño de envase | SKU | Disponibilidad | Precio |
|---|
Acerca de este artículo
Fórmula empírica (notación de Hill):
C26H43NO2
Número CAS:
Peso molecular:
401.63
UNSPSC Code:
12352204
PubChem Substance ID:
MDL number:
En este momento no podemos mostrarle ni los precios ni la disponibilidad
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarlebiological source
synthetic
assay
≥97.0% (HPLC)
form
crystals and lumps
storage temp.
2-8°C
SMILES string
CC(C)CNC(=O)[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
InChI
1S/C26H43NO2/c1-16(2)15-27-24(29)17(3)21-8-9-22-20-7-6-18-14-19(28)10-12-25(18,4)23(20)11-13-26(21,22)5/h7,16-19,21-23,28H,6,8-15H2,1-5H3,(H,27,29)/t17-,18-,19-,21+,22-,23-,25-,26+/m0/s1
InChI key
HUMXZYXRXDDZOG-LFZVSNMSSA-N
Biochem/physiol Actions
Lathosterolamide MGI-39 is an inhibitor of lathosterol oxidase which converts 5-α-cholest-7-en-3-β-ol to cholesta-5,7-dien-3β-ol. [1]
Packaging
Bottomless glass bottle. Contents are inside inserted fused cone.
signalword
Warning
hcodes
pcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Acute 1
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Ralf Klingenstein et al.
Journal of neurochemistry, 98(3), 748-759 (2006-06-06)
Prion diseases are invariably fatal, neurodegenerative diseases transmitted by an infectious agent, PrPSc, a pathogenic, conformational isoform of the normal prion protein (PrPC). Heterocyclic compounds such as acridine derivatives like quinacrine abolish prion infectivity in a cell culture model of
Martin Giera et al.
Steroids, 73(3), 299-308 (2008-01-01)
Inhibition of cholesterol biosynthesis offers the opportunity for treatment of cardiovascular diseases. Numerous enzymes are involved in the post-squalene part of this biosynthesis, and selective inhibitors for almost all of the enzymes involved there have been described in literature. The
Ken'ichi Hagiwara et al.
Biological & pharmaceutical bulletin, 30(4), 835-838 (2007-04-06)
In prion diseases, the normal cellular form of prion protein (PrP(C)) is converted into the disease-associated isoforms (PrP(Sc)) which accumulate in the infected tissues. Although the precise mechanism of this conversion remains unsolved, drugs of various categories have been reported